Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2024, 5(6); doi: 10.25236/AJMHS.2024.050603.

Exploring the Mechanism of Action of Silybum Marianum against Liver Fibrosis Based on Network Pharmacology


Liu Yuanyuan1, Huang Feng2

Corresponding Author:
Huang Feng

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

2The First Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China


Silybum marianum active ingredients were obtained and their targets of action were predicted using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the SwissTargetPrediction. And the disease targets of hepatic fibrosis were predicted through the GeneCards database, the OMIM database, and the DisGeNET database. The intersection of the hepatic fibrosis disease targets and the action targets of the active ingredients was taken after integrating.And a protein-protein interaction (PPI) network was constructed at String12.0, and then the strength of the interaction network of silybum marianum anti-hepatic fibrosis targets was determined using Cytoscape 3.9.1 software; Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed on the predicted targets of silybum marianum and the targets of hepatic fibrosis diseases using the DAVID database. The final results were visualised and presented through the SRplot website.


Silybum Marianum, Liver Fibrosis, Network Pharmacology

Cite This Paper

Liu Yuanyuan, Huang Feng. Exploring the Mechanism of Action of Silybum Marianum against Liver Fibrosis Based on Network Pharmacology. Academic Journal of Medicine & Health Sciences (2024), Vol. 5, Issue 6: 18-24. https://doi.org/10.25236/AJMHS.2024.050603.


[1] Chinese Society Of Hepatology, C.M.A., C.M.A. Chinese Society Of Gastroenterology and C.M.A. Chinese Society Of Infectious Diseases, Consensus on the diagnosis and treatment of liver fibrosis (2019)[J]. Modern Medicine and Health, 2019,35(18): 2928-2938.

[2] Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N. Management strategies for liver fibrosis[J]. Ann Hepatol, 2017,16(1): 48-56.

[3] Xu J et al, Exploring the mechanism of action of anti-fibrotic soft liver formula against liver fibrosis based on hepatic sinusoidal capillarization[J]. Journal of Clinical Hepatobiliary Diseases, 2020,36(02): 319-323.

[4] He D et al, Advances in the etiology and mechanism of liver fibrosis[J]. Journal of Kunming Medical University, 2022,43(11): 165-171. 

[5] Abenavoli L, Izzo A A, Milic N, et al. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases[J]. Phytother Res, 2018,32(11): 2202-2213.

[6] Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years[J]. Molecules (Basel, Switzerland), 2017,22(2): 191.

[7] Kroll D J, Shaw H S, Oberlies N H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies[J]. Integr Cancer Ther, 2007,6(2): 110-119.

[8] Cao Zhengmin et al. Discussion on Chinese medicine treatment of liver fibrosis from the theory of "Yang transforms qi and yin forms"[J]. Journal of Liver Diseases in Chinese and Western Medicine, 2023,33(12): 1130-1131.

[9] Wen, K. S. et al. A network pharmacology and molecular docking based study to explore the prevention of hepatic fibrosis by Chicken Bone Herb[J]. Chinese Journal of Clinical Pharmacology, 2023, 39(16): 2400-2403. 

[10] Wang, H. et al. Progress in molecular pharmacological mechanisms of antitumor, antioxidant and immunomodulatory properties of silymarin [J]. Journal of Pharmaceutical Sciences, 2010,45(04): 413-421.

[11] Baeck, C., et al., Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury[J]. Gut, 2012. 61(3): 416-26.

[12] Zhang, T.T. and Lu, X.L., Hepatoprotective drugs in metabolism-related fatty liver disease[J]. World Clinical Drugs, 2021. 42(08): 612-618.

[13] Guo, S. R. et al. Advances in pharmacological studies on the hepatoprotective effects of silymarin capsules [J]. China Hospital Drug Evaluation and Analysis, 2024. 24(01): 116-118+123.

[14] Jiang, W., Deng, Z. L. & Li, F. C., Effect of quercetin on the expression of collagen types I and III in human hepatic stellate cells with its cell cycle study[J]. Chongqing Medicine, 2018. 47(09): 1179-1182.

[15] Wang, Shaozhan et al. Quercetin exerts anti-hepatic fibrosis effects by inhibiting TGF-β/TAK1/JNK and TGF-β/Smad2 signaling pathways[J]. Zhongnan Pharmacology, 2022. 20(05): 965-972.

[16] Li Yaju, Guo Shan & Wei Feili, Activation effect of citrinin on transforming growth factor β1-induced hepatic stellate cells and gene expression profiling[J]. Chinese Journal of Liver Diseases (Electronic Edition), 2023. 15(03): 34-42.

[17] Lei, L., et al., Dihydroquercetin Activates AMPK/Nrf2/HO-1 Signaling in Macrophages and Attenuates Inflammation in LPS-Induced Endotoxemic Mice[J]. Frontiers in Pharmacology, 2020. 11: 662.

[18] Zhao M, Chen J, Zhu P, et al. Dihydroquercetin (DHQ) ameliorated concanavalin A-induced mouse experimental  fulminant hepatitis and enhanced HO-1 expression through MAPK/Nrf2 antioxidant  pathway in RAW cells[J]. Int Immunopharmacol, 2015,28(2):938-944.

[19] Yang guang and Song, Jianning, PI3K/Akt signaling pathway and endoplasmic reticulum stress in hepatocyte apoptosis in liver fibrosis rats[J]. Basic Medicine and Clinics, 2017. 37(05): 614-618.